Published in Health Insurance Law Weekly, August 14th, 2005
According to recent research from Sweden and Italy, "Murine polyomavirus (MPyV) VP1 virus-like particles (VLPs), containing a fusion protein between MPyV VP2 and the extracellular and transmembrane domain of HER-2/neu (Her2), Her21-683 PyVLPs, were tested for their ability to vaccinate against Her2-expressing tumors in two different in vivo models. Protection was assessed both against a lethal challenge with a BALB/c mammary carcinoma transfected with human Her2 (D2F2/E2) and against the outgrowth of autochthonous mammary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly